INTRODUCTION

Consequences of Immunotoxicity
A number of biological or chemical agents have the capacity to alter the functionality of the immune system in humans and animals, potentially compromising the organism's ability to recognize or neutralize infectious agents or neoplastic cells.
A number of chemical and environmental agents as well as pharmaceuticals may lead to autoimmune diseases in experimental animals or humans [Bigazzi, 1988; Kammuller et al., 1989] . The consequences regarding the effects of immunosuppression/depression in humans have been extensively studied. On the basis of epidemiological studies, a reduction in resistance to infections produced by biological agents (virus, bacteria, fungi) has been extensively described [Bowler et al., 1997] . Neoplasia can also be the result of a compromised surveillance mechanism on the part of the immune system responsible for the elimination of neoplastic cells [Tryphonas and Feeley, 2001] . Severe immunosuppression represents a well-described risk factor for the development of non-Hodgkin's lymphomas (NHL). An increase in incidence for NHL was found in AIDS patients [Beral et al., 1991; Obrams and Grufferman, 1991] , and in patients that have had immunosuppressive therapies following organ transplants [Hoover and Fraumeni, 1973; Anonymous, 1984] . Conclusive evidence is lacking, however, regarding risks associated with factors that have a modest but prolonged capacity to induce immunosuppression. Regarding chemical agents, there is some epidemiological evidence that suggests that exposure to various agents with a potential of immunotoxicity, for example, pesticides and solvents, may be associated with an increase in risk of NHL [Chiu and Weisenburger, 2003 ]. However, the data is insufficient to support a causal relationship.
Immunotoxicity Testing
Due to the complexity of the immune system, the identification of substances that induce adverse effects on the human immune system requires considering the markers according to each specific immunologic effect.
Various organizations (Organization for Economic Cooperation and Development, OECD, U.S. National Toxicology Program, NTP, Dutch National Institute of Public and the Environment, RIVM, US Food and Drug Administration, FDA, U.S. Environmental Protection Agency, EPA) that conduct testing for immunotoxicity have proposed different approaches to immunotoxicity testing that include validated immune testing protocols for both animals, as reviewed by Luster et al. [1988] and Van Loveren and Vos [1989] , and humans, as reviewed by Tryphonas, 2001 . OECD have proposed guidelines for testing the toxicity of chemicals (guideline number 407) that were adopted in many countries.
Currently, there are a number of test procedures that measure diverse immunological end points, mainly in laboratory animals, but also in humans. Tiered testing schemes, organized in stepwise protocols, have been successfully used to identify and characterize immunotoxic substances. These tests are designed to detect a change in the number of cells or the weight of an immune system organ, or to evaluate altered functionality of its components. Various agencies have adopted protocols that include specific tests classified by levels of increasing complexity. Level (or Tier) 1 is comprised of a series of preliminary tests that should indicate the absence of toxicity to the immune system, or suggest a direction for further study. The tests included in level (or Tier) 2 are meant to enhance the understanding of the nature of effect when level one tests are positive. Testing schemes for establishing immunotoxicity in humans have also been proposed [Colosio et al., 1999; Van Loveren et al., 1999] according to a 3-tier approach. There is not always general agreement, however, as to which tests fall into which levels. In any case, it is agreed that the most effective approach to immunotoxicity testing is to perform a battery of tests, and interpret them in their entirety, not on the analysis of a single parameter [Dean, 1979; Vos, 1980; Luster et al., 1988] .
Objectives
The purpose of this study is to provide a documentation on immunotoxicity of substances that are widely used in work environment, by building tables for each chemical of interest and the preparation of a matrix that includes information on the immune category affected, the type of effect, and the strength of evidence for each chemical, and subsequent scoring the substances for their immunotoxicity evidence, power and type of effect. It is intended to use the matrix in interpreting the role of adverse immune effects of exposures to a variety of industrial chemical compounds on the induction of different diseases including neoplasms. The matrix will be used to estimate relative risks by considering the immunotoxicity evidence, the power and type of immunotoxic effect of each agent to which an individual has been exposed in the context of epidemiological studies, as the ''Italian multicenter casecontrol study on hematolymphopoietic malignancies in Italy and exposures to solvents and pesticides'' [Seniori Costantini et al., 2001] where detailed information on chemical exposures (intensity and probability) has been collected. Substances has been selected on the basis of the number of workers exposed. Currently only chemical compounds used in industrial settings have been considered. Subsequently it is intended to take pesticides into consideration as well.
MATERIALS AND METHODS
The first step was to prepare summary tables on immunotoxicity testing given the complexity of the immune system. A large part of information came from the Environmental Health Criteria documents published by the World Health Organization, ''Principles and Methods for Assessing Direct Immunotoxicity Associated with Exposure to Chemicals'' [International Programme on Chemical Safety [WHO, 1996] , and ''Principles and Methods for Assessing Hypersensitization Associated with Exposure to Chemicals'' [International Programme on Chemical Safety [WHO, 1999] . A section of these texts provides an overview of the testing strategies for detecting immunotoxicity adopted by various organizations. These testing methods are discussed, often with an evaluation of their efficacy. In constructing the tables, these two texts were consulted to identify and describe test characteristics and the immune response category that is represented by each test. The report of validation study of assessment of direct immunotoxicity in the rat by the International Collaborative Immunotoxicity Study (ICICIS) group investigators was also consulted in order to collect evaluation of performance of various experimental techniques used in the rats to indicate toxic effects on the immune system [ICICIS Group Investigators, 1998 ]. This information has been updated with more current information obtained from consulting the web sites of the various organizations cited, when available, and with other information obtained by Medline searches for immunotoxicity testing procedures.
In these summary tables, various tests that are used in immunotoxicology research in animals and in humans are summarized. They include, in addition to the principal characteristics regarding each test, basic information on the validation that each test has undergone regarding its ability to determine adverse effects on the immune system. The following information was included: (i) the immune category evaluated by each test; (ii) specific test; (iii) organs, cells or other parameters affected; (iv) principal effects on the immune system; (v) organizations that recommend or mention the use of these tests, and when considered, the level or tier attributed to this test.
The second step consisted in the preparation of substance-specific tables for 20 substances of interest. Substances were chosen on the basis of the most frequent chemicals reported in the working histories of cases and controls enrolled and interviewed in the context of the ''Multicenter case-control study on hematolymphopoietic malignancies in Italy.'' For each substance the literature available was reviewed and results were summarized taking into account the type of immunotoxicity and strength of evidence and power. The ''substance tables'' have been realized essentially with the information collected from documents of the Agency for Toxic Substances and Disease Registry (ATSDR). In particular the paragraphs dealing with immunological and lymphoreticular effects in the toxicological profiles on the each substances have been considered. Other information has been found from the environmental health criteria (EHC) monographs and from ''abstracts'' and/or from ''full texts'' of relevant papers through consultation of ''Pubmed'' and ''Toxnet.''
The third step was the classification of the 20 substances of interest on the basis of the evidence of immunotoxicity, expressed by end-points, considering the capacity of the tests to predict the immunotoxicity (for instance: the effects on host resistance weigh more heavily than effects on pathology). The end-points have been identified on the basis of the existing literature and indications supplied from an expert immunotoxicologist. Criteria to define evidence of immunotoxicity are shown in Table I . An index was assigned in order to classify different substances: strong, intermediate, weak, nil.
Substances with the same index of evidence (i.e., Benzene, Trichloroethylene, Crystalline silica, and PHAs that have all been classified ''strong'') were compared pair-wise in order to produce a score for each chemical. Scoring was done considering doses (minimal doses at which the effects are seen), but the route of administration was also considered (main route of exposure). The number of positive studies and of species (mice, rats, pigs, humans) was also taken into account in scoring substances. Formally chemicals can be adequately compared for their effects (comparable magnitude of effects and of doses that produce same effects) if similar endpoints are compared and if tests are performed under similar conditions and similar routes of exposure (i.e., inhalation compared with inhalation). This is not always possible in a straightforward way, and experts have provided further contributions. Substances were classified also for the type of immunotoxic effects. The type of immunotoxic effect has been assigned independently from the immunotoxic evidence. This work has taken in consideration also those studies that provide indications on the various types of immunotoxicity, (as an example the test that finds the level and the type of autoantibody provides information on alterations of autoimmunity type). Several positive studies with highly predictive tests for autoimmunity evaluation have been taken into consideration, even if these tests are not always recommended by the agencies for immunotoxicity evaluation. As an example, crystalline silica has been classified as ''strong,'' because two tests (Host resistance and DHR) that satisfy criteria of high predictability are positive. Its effects on the immune system are mainly of autoimmunity. A document of the U.S. FDA (FDA, 1999; Guidance for Industry and FDA reviewers-Immunotoxicity testing) has used potential immunotoxic effects associated with immune responses to evaluation of type of immunotoxic effect.
Criteria for classification of immune response associated with potential immunotoxic effects are shown in Table II .
RESULTS
A total 321 studies were reviewed of which 227 were animal studies and 94 human studies related to the 20 substances of interest. Human studies were related mainly to crystalline silica and asbestos. Human studies included tests on humoral and cellular mediated immunity (antibody levels in serum or in fluid, surface marker analysis, cytokine synthesis patterns, cytokine expression patterns, T-and B-cell mitogen assay), and non-specific cellular mediated immunity (NK cells activity: cytotoxicity, degranulation of granulocytes: basophils or eosinophils), and test on autoimmunity evaluation (autoantibodies titers in serum). Twenty tables have been produced that include information collected for the 20 substances of interest. These tables include information on the immune category evaluated by each test, organs, cells, or other targets, principal effects on the immune system, doses, routes of exposure for each specific assay. References for each study and specific to the organizations that recommend or mention the use of these tests, and, when considered, the [Li, 1992] a Body weight: upto100 mg/kg/day,12 months or2 years, (oral) in rats [NTP, 1986] Cellularity (spleen) T-cell: at 31ppm, 6 days, and at 300 ppm, 2^5 weeks, (inhalation) in mice [Rozen et al., 1984] Cellularity (bone marrow): at 25 ppm, 2 weeks Cellularity B,Tand Tcell subset (spleen): at100 ppm, 20 days (inhalation) in mice [Rosenthal and Snyder, 1987] Cellularity B lymphocytes (bone marrow): at10 ppm, 6 days, (inhalation) in mice [Rozen et al.,1984] Cellularity (bone marrow) at 25 ppm, 2 weeks (inhalation) in mice [Cronkite et al., 1985] Cellularity ( Wells and Nerland [1991] (2) Klan et al. [1990] (b) Aoyama [1986] (c) Aksoy et al. [1987] a (d) Aksoy et al. [1971 Aksoy et al. [ , 1972 Aksoy et al. [ ,1974 a (e) (1) Mitogenic response (T-cell) lymphocyte to PHA (peripheral blood): (occupational) humans [Yardley-Jones et al.,1988] PFC to SRBC: at 400 ppm, 2 or 4 weeks (inhalation) in rats Host resistance s. zooepidemicus: at10 ppm, 1or 5 days (inhalation in mice) [Aranyi et al., 1989] (a) Macrophage activity (bone marrow) Rozen et al. [1984] (b) Rozen and Snyder [1985] (c) Hsieh et al. [1990] Surface markers:
(a) CD4/CD8 ratio (peripheral blood) (a) Increase in CD4, increase in ratio (a) 300 or 900 ppm, 5 days. Rosenthal and Snyder [1985] (c) Rosenthal and Snyder [1987] a This information is taken directly the publication: US Department of Health and Human Services, Public Health Services, Agency forToxic Substances and Disease Registry (ATSDR) ''Toxicological Profile for Benzene'' . September1997. 
DISCUSSION
A matrix on immunotoxicity that can be used in epidemiological studies in which information on chemical exposures has been constructed. This matrix can represent a tool to identify chemicals with similar immunotoxic properties and thus to improve risk estimations for immune-related diseases. Information was systematically reviewed and summarized. Weight of evidence (end points), doses to which adverse effects were observed and type of immunotoxic effects were considered in order to classify chemicals by their immunotoxic potential. The presence of positive studies that examined immunotoxicity in highly predictive tests provided greater weight, as well as positive studies in human beings.
Limitations of this study include some discrepancies in the results of studies on which the matrix is based. Some effects of a given agent on immune function may result from differences in the experimental system used by different investigators and laboratories that generated the published information examined (there can be significant variability in some of these tests, from laboratory to laboratory), rather than reflect real differences in the biological effects of these toxic agents. There is a random aspect in the weight of evidence: some substances may have been studied less broadly or have gained less attention just by chance, selection of types of studies depends on research group.
A second problem consists in the fact that different tests have been performed for different chemicals in most cases, making it difficult to compare substances. Moreover, most chemicals tested can show more different types of immunotoxic effects (i.e., immunosuppression and stimulation), depending on dose. Another problem is that conflicting results for the same substances emerged for different endpoints depending on different doses, route of exposure, species (human, animal).
Finally, the issue of potential differences in how toxic agents may affect murine versus human immune systems is raised. The proposed classification provides more information than that usually offered by the current literature on toxicity of chemicals as for immunotoxicants estimates risk in epidemiological studies.
CONCLUSION
This matrix will be used in the ''Multicenter case-control study on hematolymphopoietic malignancies in Italy'' to estimate relative risks by considering the immunotoxicity evidence and type of immunotoxic effects of each agent to which individuals have been exposed. Cumulative exposure to each chemical classified for its effect on immune system will be estimated, in addition to peaks of exposure to strong immunotoxic agents. Once validated the matrix will be made available for other epidemiological studies in which immunotoxicity of chemicals is of concern. 
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